https://uthandonethemba.com/2026/09/15/mitiperstat-hfpef-two-gates/Uthando Nethembaen2026-09-15T04:09:37+00:00Two Gates in Heart Failure: A Drug That Bound Its Target and Still Failed, and One That Passed Its Trial and Still Split on Reimbursementheart failure, finerenone, cardio-renal-metabolic, HFpEF, myeloperoxidase, MPO inhibitor, target validation, informative null, phase 2b trial, ENDEAVOR trial, nonsteroidal MRA, health technology assessment, IQWiG, NICE